Conexeu Sciences Inc. (CNXU) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CNXU scores 43 out of 100, earning a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

• Fundamental Cash Engine: 10 / 20 (ROIC 0%; FCF yield 0%). The cash-generation pillar is weak; the source reports no return on invested capital and no free-cash-flow yield, meaning the business is not currently converting capital into measurable returns per the Roarable RQD rating.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the lowest pillar. Per the Roarable RQD rating, institutional flow is a weak signal, though the holders section of the source data contains no 13F detail (see Analyst View below).
• Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signal is below midpoint.
• Macro Regime Fit: 8 / 20 (beta 1.0; sector sensitivity). Per the Roarable RQD rating, the stock tracks the market at beta 1.0 with limited regime advantage.
• Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar. Per the Roarable RQD rating, the balance sheet is the main offset to weak cash generation and flow.

For a prospective investor evaluating the stock today, the rating points to a stock whose fundamental and flow signals are both weak, with balance-sheet resilience as the primary support. The upside case depends on the company converting its financial posture into operating returns, which the current source data does not show. Valuation cannot be assessed on earnings because P/E and EPS are not available in source data. The stock trades at $2.83 against a 52-week range of $2.43 - $18.79, placing it near the bottom of its annual band per the market data section. This is an analytical framing, not personalized financial advice.

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with EPS, FCF, cash, and debt not reported. Per the market data section, gross, operating, and net margins are each 0% and ROIC is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5 under its forensic balance sheet pillar. The source data does not provide the underlying balance-sheet line items that would let these scores be independently verified.

Per the recent news section, the headlines are as follows, all carrying a YELLOW light and MARKET WIRE impact label:

• A TradingView estimates report on CNXU (1h ago).
• A Simply Wall St piece asking when the company will become profitable (3h ago). The headline itself signals that profitability is not yet established.
• A MarketBeat competitor listing for 2026 (6h ago).
• A Stock Titan report describing a roughly $5 million financing with $250,000 held pending a shareholder vote (9h ago). This is the most material catalyst in the feed because it indicates pending dilution-related action subject to shareholder approval.
• A Simply Wall St report on an independent director acquiring 5.6% more stock (12h ago). This is a positive insider-conviction signal.
• A Benzinga intraday health care movers report (15h ago).

Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND labeled "MACRO TAILWIND SCORE (96/100)," with severity 94 and direction BULLISH. The associated headline reads that CNXU's macro tailwind is at 96/100 despite a net liquidity dip to $5,746B (-0.64% 4W). The forensic brief cites a statistical z-score of 6.1, a liquidity elasticity of 6.00x beta, and an inverse Pearson r of -0.33 between the tailwind score and net liquidity. Per the same graph, high-yield OAS expanded by 2 bps. The signal's bullish label conflicts with the negative correlation and the contraction in net liquidity it describes; the source does not reconcile this.

• What is the size, price, and dilution impact of the roughly $5 million financing, and when is the shareholder vote on the held $250,000?
• What does the company sell and to whom, and what drives any revenue, given reported FY 2025 revenue of $0.0M?
• Why does the Butterfly liquidity signal read BULLISH while its own correlation is negative, and what is the underlying methodology?
• What are the cash, debt, and free cash flow line items behind the Altman Z, Piotroski F, and Debt/Equity figures?
• What insider Form 4, 13F, and Congressional transactions drive the insider and whale pillar scores?